ASH 2025 Expert Insights: New Approach to CALR-Mutant Myelofibrosis

2025 American Society of Hematology Expert Insights: New Approach to CALR-Mutant Myelofibrosis This conversation features Gabriela Hobbs, MD (Massachusetts General Hospital), and Aaron Gerds, MD (Editor-in-Chief of ASH Clinical News), discussing early clinical insights on a targeted antibody therapy for mutant CALR in myelofibrosis. This video serves as one installment in a multi-part series of expert conversations and study highlights from the 2025 American Society of Hematology (ASH) Annual Meeting. Subscribe for ongoing conference coverage and perspectives from leaders at the forefront of hematology and cellular therapy. 🎤 Speaker: Gabriela Hobbs, MD, Massachusetts General Hospital 🎤 Interviewer: Aaron Gerds, MD, Editor-in-Chief, ASH Clinical News The discussion centers on first-in-human findings for an investigational antibody designed to selectively target mutant calreticulin in patients with myelofibrosis. Early-phase results suggest the therapy was generally well tolerated, both on its own and in combination with ruxolitinib, in patients with limited treatment options. 📖🔗 Read the full article: “Early Data Show Mutant CALR-Specific Monoclonal Antibody Well Tolerated in Myelofibrosis” https://ashpublications.org/ashclinic... 📚🔗 Want more? Discover more Hematology insights: https://focus.wiley.com/topic/amps-su... This discussion is intended for hematologists, oncologists, cellular therapy specialists, and clinical researchers who want expert commentary on CAR-T therapy, neurotoxicity, and evolving strategies in multiple myeloma care. #Hematology #ASH #ASH2025 #myelofibrosis #JAKi #CALR #thrombocythemia